title: Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
abstract: BACKGROUND
  Chemoresistance is a major challenge in cancer treatment. miR-506 is a potent inhibitor of the epithelial-to-mesenchymal transition (EMT), which is also associated with chemoresistance. We characterized the role of miR-506 in chemotherapy response in high-grade serous ovarian cancers.
  
  
  METHODS
  We used Kaplan-Meier and log-rank methods to analyze the relationship between miR-506 and progression-free and overall survival in The Cancer Genome Atlas (TCGA) (n = 468) and Bagnoli (n = 130) datasets, in vitro experiments to study whether miR-506 is associated with homologous recombination, and response to chemotherapy agents. We used an orthotopic ovarian cancer mouse model (n = 10 per group) to test the effect of miR-506 on cisplatin and PARP inhibitor sensitivity. All statistical tests were two-sided.
  
  
  RESULTS
  MiR-506 was associated with better response to therapy and longer progression-free and overall survival in two independent epithelial ovarian cancer patient cohorts (PFS: high vs low miR-506 expression; Bagnoli: hazard ratio [HR] = 3.06, 95% confidence interval [CI] = 1.90 to 4.70, P < .0001; TCGA: HR = 1.49, 95% CI = 1.00 to 2.25, P = 0.04). MiR-506 sensitized cells to DNA damage through directly targeting the double-strand DNA damage repair gene RAD51. Systemic delivery of miR-506 in 8-12 week old female athymic nude mice statistically significantly augmented the cisplatin and olaparib response (mean tumor weight ± SD, control miRNA plus cisplatin vs miR-506 plus cisplatin: 0.36±0.05g vs 0.07±0.02g, P < .001; control miRNA plus olaparib vs miR-506 plus olaparib: 0.32±0.13g vs 0.05±0.02g, P = .045, respectively), thus recapitulating the clinical observation.
  
  
  CONCLUSIONS
  MiR-506 is a robust clinical marker for chemotherapy response and survival in serous ovarian cancers and has important therapeutic value in sensitizing cancer cells to chemotherapy.
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Guoyan
authors.initials: G
authors.lastname: Liu
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Da
authors.initials: D
authors.lastname: Yang
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Rajesha
authors.initials: R
authors.lastname: Rupaimoole
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Chad V
authors.initials: CV
authors.lastname: Pecot
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Yan
authors.initials: Y
authors.lastname: Sun
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Lingegowda S
authors.initials: LS
authors.lastname: Mangala
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Xia
authors.initials: X
authors.lastname: Li
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Ping
authors.initials: P
authors.lastname: Ji
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: David
authors.initials: D
authors.lastname: Cogdell
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Limei
authors.initials: L
authors.lastname: Hu
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Yingmei
authors.initials: Y
authors.lastname: Wang
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Cristian
authors.initials: C
authors.lastname: Rodriguez-Aguayo
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Gabriel
authors.initials: G
authors.lastname: Lopez-Berestein
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Ilya
authors.initials: I
authors.lastname: Shmulevich
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Loris
authors.initials: L
authors.lastname: De Cecco
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Kexin
authors.initials: K
authors.lastname: Chen
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Delia
authors.initials: D
authors.lastname: Mezzanzanica
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Fengxia
authors.initials: F
authors.lastname: Xue
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM).
authors.forename: Anil K
authors.initials: AK
authors.lastname: Sood
authors.affiliation: : Departments of Pathology (GL, DY, YS, XL, PJ, DC, LH, WZ), Experimental Therapeutics (CRA, GLB), and Gynecologic Oncology and Reproductive Medicine (RR, LSM, AKS), Division of Cancer Medicine (CVP), Center for RNAi and Non-Coding RNA (RR, CVP, LSM, CRA, GLB, AKS, WZ), the University of Texas MD Anderson Cancer Center, Houston, TX; Department of Gynecology and Obstetrics, Tianjin Medical University General Hospital, Tianjin, China (GL, YW, FX); Department of Pathology (YS) and Epidemiology (KC), Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Department of Biochemistry and Molecular Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an, China (XL); Institute for Systems Biology, Seattle, WA (IS); Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (LDC, DM). wzhang@mdanderson.org.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D004249:DNA Damage / Q000187:drug effects* / Q000235:genetics; D004273:DNA, Neoplasm / Q000187:drug effects*; D004357:Drug Synergism; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006367:HeLa Cells; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D051379:Mice; D008819:Mice, Nude; D035683:MicroRNAs / Q000378:metabolism / Q000494:pharmacology*; D008856:Microscopy, Fluorescence; D060787:Neoplasm Grading; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental; D016017:Odds Ratio; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D010793:Phthalazines / Q000008:administration & dosage / Q000494:pharmacology; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D051135:Rad51 Recombinase / Q000187:drug effects / Q000378:metabolism*; D060888:Real-Time Polymerase Chain Reaction; D046888:Tissue Array Analysis; D014410:Tumor Stem Cell Assay
chemical_list: D014408:Biomarkers, Tumor; D004273:DNA, Neoplasm; C561508:MIRN506 microRNA, human; D035683:MicroRNAs; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C495153:RAD51 protein, human; D051135:Rad51 Recombinase; D002945:Cisplatin; C531550:olaparib